A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.775
Abstract: Tezepelumab, a human immunoglobulin G2 monoclonal antibody against thymic stromal lymphopoietin, is currently under clinical development for the treatment of severe, uncontrolled asthma. This phase 1, randomized, placebo‐controlled, single‐ascending‐dose study assessed the safety, tolerability, pharmacokinetics,… read more here.
Keywords: placebo; safety; phase randomized; healthy japanese ... See more keywords
Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2019.1672657
Abstract: ABSTRACT Introduction: Thymic stromal lymphopoietin (TSLP) is overexpressed in the airways of severe asthmatics and is an upstream cytokine that orchestrates inflammatory responses in asthma. TSLP exerts its effects by binding to a high affinity… read more here.
Keywords: therapy; severe uncontrolled; uncontrolled asthma; tezepelumab ... See more keywords
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2074195
Abstract: Abstract Aims To compare the efficacy of tezepelumab with other approved biologics via indirect treatment comparisons (ITCs) in patients aged ≥ 12 years with severe uncontrolled asthma. Materials and methods Data from randomized controlled trials (RCTs)… read more here.
Keywords: tezepelumab; treatment comparison; review; indirect treatment ... See more keywords
Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.oa3189
Abstract: Background: Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine and key regulator of inflammatory pathways including type 2 responses. Tezepelumab is a human anti-TSLP monoclonal antibody that reduces the early and late phase asthmatic responses… read more here.
Keywords: efficacy safety; severe asthma; study; adults severe ... See more keywords
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Research"
DOI: 10.1186/s12931-020-01541-7
Abstract: Background Tezepelumab is a human monoclonal antibody that blocks the activity of the epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid-sparing potential of tezepelumab are being investigated in two ongoing, phase 3,… read more here.
Keywords: destination; long term; placebo; safety ... See more keywords
Tezepelumab for asthma.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.12.3449205
Abstract: The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can promote and regulate inflammatory processes through the production of cytokines, namely interleukin… read more here.
Keywords: tezepelumab; tslp; inflammatory processes; tezepelumab asthma ... See more keywords
Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Asthma and Allergy"
DOI: 10.2147/jaa.s378062
Abstract: Abstract Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. It was approved by the United States Federal Drug Administration (US FDA) as an… read more here.
Keywords: tezepelumab; asthma; patients severe; analysis ... See more keywords